Inhibition of the proteasome reduces transfer-induced diabetes in nonobese diabetic mice

J Petrovic1, H Hall, R Mehr

  • 1Microbiology and Tumor Biology Center, Karolinska Institutet, S-171 77 Stockholm, Sweden.

Insights

Proteasome inhibition with MG132 significantly reduced transfer-induced diabetes in mice by targeting T cell proliferation. This suggests the proteasome plays a key role in the development of this autoimmune disease.

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • The 26S proteasome is implicated in various immune-mediated diseases.
  • Its role in transfer-induced diabetes, an autoimmune condition, is not well understood.

Purpose of the Study:

  • To investigate the proteasome's role in regulating transfer-induced diabetes.
  • To evaluate the therapeutic potential of proteasome inhibitors in this condition.

Main Methods:

  • Treatment of nonobese mice with the proteasome inhibitor MG132.
  • Assessment of diabetes incidence and severity.
  • In vitro and in vivo analysis of T cell proliferation and migration.

Main Results:

  • MG132 treatment reduced transfer-induced diabetes by 76%.
  • MG132 inhibited T cell proliferation in pancreatic lymph nodes and in vitro.
  • MG132 did not affect T cell migration but reduced severe islet infiltration.

Conclusions:

  • The proteasome regulates transfer-induced diabetes.
  • MG132 demonstrates therapeutic potential by targeting autoreactive T cells.
  • Proteasome inhibition may be a viable strategy for treating autoimmune diabetes.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.